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DOI 10.1186/s12944-017-0617-0RESEARCH Open AccessEffects of 12-week supplementation of
marine Omega-3 PUFA-based formulation
Omega3Q10 in older adults with
prehypertension and/or elevated blood
cholesterol
Tian Shen1†, Guoqiang Xing2,3*† , Jingfen Zhu1†, Shuxian Zhang1, Yong Cai1,8*, Donghua Li4, Gang Xu1,
Evan Xing5, Jianyu Rao6 and Rong Shi7Abstract
Backgrounds: To study the effects of supplementation of a marine omega-3 poly-unsaturated fatty acids (n3-PUFA)
formulation (Omega3Q10) in older adults with hypertension and/or hypercholesterolemia.
Methods: A total of 97 people were enrolled to receive 12-week supplementation of either Omega3Q10 (n = 48) or
soybean oil (n = 49). Total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein
cholesterol (HDL-C), and hypertension-related symptoms were determined before and after the supplementation.
Results: There were no baseline differences between the two groups. Omega3Q10 supplementation significantly
reduced diastolic blood pressure (DBP) (from 81.6 ± 5.3 mmHg to 79.3 ± 5.2 mmHg, P < 0.05). Blood concentrations
of TC and LDL-C decreased significantly and blood HDL-C level increased significantly after 12 weeks of Omega3Q10
(5.5 ± 0.7 vs. 5.3 ± 0.5, P < 0.05; 3.7 ± 0.8 vs. 3.3 ± 0.6, P < 0.05; 1.2 ± 0.6 vs. 1.3 ± 0.5, P < 0.05, respectively) and soybean oil
supplementation (5.7 ± 0.8 vs. 5.6 ± 0.7, P < 0.05; 3.6 ± 0.7 vs. 3.4 ± 0.8, P < 0.05; 1.0 ± 0.8 vs. 1.2 ± 0.7, P < 0.05,
respectively) but no group differences were found. A significantly greater proportion of the people in the
Omega3Q10 group became free from headache and palpitations & chest tightness symptoms after the 12-week
supplementation compared to that of the soybean oil group (95.5% vs. 71.4%, P < 0.01; 95.8 vs. 75.5%, P < 0.01,
respectively).
Conclusion: 12-week supplementation of Fish oil-based PUFA appear to be more effective in improving DBP and
hypertension-related symptoms than soybean oil in old adults with hypertension and hypercholesterolemia although
both supplementation improved TC, LDL-C and HDL-C concentrations.
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Elevated blood-pressure or blood cholesterol levels are
major risk factors for cardiovascular events that are the
major cause of death worldwide [1]. Hypertension that de-
velops over time without a specific cause is considered be-
nign hypertension. The common manifestations of
hypertension include dizziness, headache, fatigue, tinnitus,
palpitations & chest tightness, and lassitude in the loins
and knees. It is estimated that more than one third of adults
living in the US and China has hypertension or hyperchol-
esterolemia, most of whom remain untreated [2, 3].
While modification of lifestyle, including low-sodium
intake, high potassium diet, increasing physical activity,
quitting smoking, reducing alcohol consumption, and
maintaining a healthy weight can lower the risk of one’s
progression of hypertension, many people experience
difficulties to change their habits [4, 5]. Recent studies
suggest that dietary supplementation of certain nature
products, such as fish oil-derived Omega-3 polyunsat-
urated fatty acids (n-3 PUFA) [6–10] and/or plant
derived-PUFA, phospholipids, sterols and stanols can
be beneficial on blood cholesterol and blood pressure
[11–26]. However, controversy still remains around
the cardioprotective effects of fish oil-derived n3-
PUFA [27–29] probably due to heterogeneous nature
in the selection of different participants, formulation
of different supplements, background diet, ratio of
n3-PUFA: n6-PUFA and outcome measures [30–32].
The aim of this observational study was to evaluate
the effects of supplementation of Omega3Q10, a fish oil-
based Omega-3 n-3 PUFA formulation and soybean oil
control in older adults with elevated blood pressure and
blood cholesterol.
Methods
Study population
The recruitment of the participants into the study was
started on September 2, 2013 and completed on October
12, 2013, and the last follow-up observation was com-
pleted on January 7, 2014, at Tang-Qiao Community
Health Service Center in Pudong New District in Shang-
hai, China. Volunteers were recruited by self-referral in
response to media coverage and word of mouth. All
study procedures were conducted in accordance with
the Helsinki Declaration of 1975 and were approved by
the Shanghai Jiao Tong University School of Public
Health Institutional Review Board. Written informed
consent form was obtained from all participants prior to
enrollment into the study.
Subjects who met the first and one of other three
following criteria were eligible for the study:
Inclusion criteria:
1) Healthy males or females at least 50 years of age;2) Having current symptoms of elevated blood pressure
(systolic blood pressure 130–139 mmHg or diastolic
blood pressure 85-89 mmHg);
3) Having a history of elevated blood pressure (systolic
blood pressure 140-159 mmHg or diastolic blood
pressure 90-99 mmHg);
4) Having a history of elevated blood cholesterol (total
cholesterol (TC) concentrations higher than normal
range: 2.8 to 5.7 mmol/L; HDL-C: 0.78 to
1.55 mmol/L; LDL-C: 1.68 to 4.53 mmol/L; glucose:
3.9 to 6.1 mmol/L).
Exclusion criteria:
1) Having diagnosed with any severe medical
conditions or complications of the liver, kidneys,
heart, lungs, or any other organs, or malignant
tumors;
2) People who have much doubts of the study, unwilling
to participate or unlikely to keep adherence of the
study procedure were also excluded.
Randomization and blindness
Participants were randomly assigned to the Omega3Q10
treatment group or soybean oil control group. The
randomization was performed using a predetermined
randomization code which was generated by a random
number generator.
Trial participants and community doctors were both
blinded from the treatment (double-blind trial). Of the
100 enrolled participants, 97 participants completed the
12-week follow-up, including 48 subjects in the Ome-
ga3Q10 group and 49 subjects in the control group.
Two subjects of the Omega3Q10 group and 1 subject of
the soybean oil control group withdrew from the study
due to objections by family members.
The participants received similar-looking capsules in
color-coded bottles (white bottles for Omega3Q10 and
yellow bottles for soybean oil control). Neither the sub-
jects nor the medical doctors, including the study princi-
pal investigator (R.S.), knew the specific color code until
the end of the study. Both the Omega3Q10 capsules and
the control capsules (which was composed of soybean
oil) were manufactured and supplied by GardaVita® Inc.
(Costa Mesa, California, USA). Each participant was
instructed to take 1 capsule with a meal, two times per
day for 12 weeks and a new batch of supplements was
dispensed every month during follow-up sessions.
The key active ingredients of Omega3Q10 formulation
include Omega-3 fish oil (1000 mg/day) (including EPA
(eicosapentaenoic acid, 312 mg), DHA (docosahexaeonic
acid, 202 mg), Omega3Q10 complex (L-carnitine fumar-
ate, Co-enzyme Q10, lycopene, 265 mg), vitamin E
(alpha tocopherol acetate and natural tocopherol oil,
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B12 (methylcobalamin, 500 mcg) and folic acid (400
mcg). Each soybean oil capsule includes 910 mg soybean
oil (saturated fatty acids 31.3 mg); monounsaturated
fatty acids (45.57 mg); polyunsaturated fatty acids
(229.48 mg); oleic acid (48 mg).
Evaluation of blood pressure, blood lipids/ cholesterols
and quality of life
Blood concentrations of TC, LDL-C, HDL-C were evalu-
ated before and after the 12-week treatment. Changes in
blood pressure and in elevated blood pressure-related
symptoms including headache, dizziness, tinnitus, palpita-
tions, and chest tightness were evaluated before and after
the 12-week intervention. Measurement of baseline blood
pressure, and the measurement of the final blood pressure
were both repeated twice with each repeat separated by a
1-week time interval. Elevated blood pressure-associated
symptoms i.e. dizziness, headache, tinnitus, palpitations
and chest tightness were scored using a self-administered
6-point scale (0 = no symptoms, 5 =most severe). All par-
ticipants were followed up each month in order to check
compliance and adverse effects.
Statistics analysis
EpiData 3.1 software was used for the data entry and
SPSS 20 software was used for statistical analysis. Group
data were presented as the mean ± standard deviation or
median ± Quartile Range (QR). Differences between the
Omega3Q10 and soybean oil groups were compared
using Student’s t-test for quantitative variables with nor-
mal distribution and Mann-Whitney U test for variables
with non-normal distribution, or Chi-square test for
categorized variables. Ridit scoring test, which is a non-
parameter test for comparing two or more sets of
ordered qualitative data, was used for evaluating the
changes in the symptom severity scores after the inter-
vention. A multivariate regression analysis was also per-
formed in order to evaluate the role of confounding
factors on final results. The alpha level of P > 0.05 was
chosen as being statistically significant. All p-values re-
ported were 2-sided.
Results
Demographic characteristics
The baseline information of age, gender and histories of
alcohol intake, disease and medication of the partici-
pants are shown in Table 1. There were 24 males (50%)
and 24 females (50%) in the Omega3Q10 group, and 24
males (48.98%) and 25 females (51.02%) in the soybean
oil group. The gender distribution between the two
groups was not significantly different between the two
groups (χ2 = 0.10, P = 0.920). The average age of all par-
ticipants was 62.83 ± 10.16, and no significant differencefor age was found between the Omega3Q10 group
(63.26 ± 10.34 years) and the soybean oil group (62.41 ±
10.10 years) (t = 0.411, P = 0.682).
There were no significant differences between Ome-
ga3Q10 and soybean oil groups in the patterns of alco-
hol drinking (22.9% vs. 24.5%) (χ2 = 0.033, P = 0.855),
smoking (22.9% vs. 20.4%) (χ2 = 0.09, P = 0.764), med-
ical history of elevated blood pressure (39.6% vs. 46.9%)
(χ2 = 0.534, P = 0.465), hypercholesterolemia (45.8% vs.
32.7%) (χ2 = 1.768, P = 0.184), coronary heart issues
(6.2% vs. 16.3%) (χ2 = 2.449, P = 0.118), stroke (2.1% vs.
6.1%) (χ2 = 0.24, P = 0.624), diabetes (6.2% vs. 8.2%)
(χ2 = 0.0, P = 1.00), and other health-related concerns
(2.1% vs. 2.0%) (χ2 = 0.0, P = 1)(Table 1).
There were no significant differences between Ome-
ga3Q10 and soybean oil groups in the proportion of the
participants who used anti-hypertensive medicine (35.4%
vs. 46.9%,χ2=1.328,P = 0.249, Renin-angiotensin system
inhibitors (ACEI/ARB): 20.83% vs. 20.41%; calcium
channel blockers: 10.42% vs. 16.33%; Diuretics: 2.08% vs.
4.8%; β-blockers: 2.04% vs. 1.03%% and other anti-
hypertensive medicine: 2.04% vs. 4.08%), the number
of years of anti-hypertensive medicine use (5.7 ± 4.0
vs. 5.8 ± 6.7,Z = 0.793,P = 0.428), the proportion of the
participants who used cholesterol lowering drugs
(6.7% vs. 11.6%, χ2=0.192,P = 0.661) and the year of
cholesterol lowering drug use (1.4 ± 1.4 vs. 2.5 ± 4.2,t =
0.426, P = 0.685).
Blood lipids/cholesterol levels
There are no significant differences between Ome-
ga3Q10 and soybean oil groups in baseline blood choles-
terol (5.5 ± 0.7 mmol/L vs. 5.7 ± 0.8 mmol/L) (P > 0.05),
HDL (1.3 ± 0.6 mmol/L vs. 1.0 ± 0.8 mmol/L) (P > 0.05),
and LDL (3.7 ± 0.8 mmol/L vs. 3.6 ± 0.7 mmol/L), (P >
0.05), nor in post-treatment blood cholesterol (5.3 ±
0.5 mmol/L vs. 5.6 ± 0.7 mmol/L) (P > 0.05), HDL (1.3 ±
0.5 mmol/L vs. 1.2 ± 0.7 mmol/L) (P > 0.05), and LDL
(3.3 ± 0.6 mmol/L vs. 3.4 ± 0.8 mmol/L) (P > 0.05)
(Table 2). Both Omega3Q10 and soybean oil treatments,
however, significantly reduced cholesterol and LDL-C
and increased HDL-C (P < 0.05, each), with a relatively
greater reduction of TC and LDL-C found in the Ome-
ga3Q10 group than in soybean oil group.
Blood pressure
The mean values of systolic blood pressure (SBP) and
diastolic blood pressure (DBP) of the Omega3Q10 group
and the soybean oil group before and after the 12-week
treatment are shown in Table 3. There were no baseline
differences between the Omega3Q10 and soybean oil
groups in SBP (132.3 ± 5.5 vs.131.8 ± 9.3, P > 0.05) and
DBP (81.6 ± 5.3 vs. 80.4 ± 6.1, P > 0.05) (Table 3), nor
after the 12-week treatment in SBP (130.7 ± 7.3 vs.
Table 1 Demographics and medical history of the participants
Group Male Female Sub Total
Gender, N (% of subtotal) Omega3Q10 24 (50.0%) 24 (50.0%) 48 (100%)
Soybean oil 24 (48.98%) 25 (51.02%) 49 (100%)
Combined 48 (49.48%) 49 (50.52) 97 (100%)
Age, year (mean ± s.d) Omega3Q10 63.87 ± 10.33 62.66 ± 10.54 63.26 ± 10.34
Soybean oil 60.67 ± 9.47 64.07 ± 10.60 62.41 ± 10.10
Combined 62.27 ± 9.93 63.38 ± 10.48 62.83 ± 10.16
Age, year (range) Omega3Q10 50.06–83.30 45.39–84.32 45.39–84.32
Soybean oil 48.90–77.91 49.81–83.79 48.90–83.79
Combined 48.90–83.30 45.39–84.32 45.39–84.32
Smoking, Yes/total (%) Omega3Q10 11/24 (45.83) 0 11/48 (22.92)
Soybean oil 10/24 (41.67) 0 10/49 (20.41)
Combined 21/48 (43.75) 0 23/97 (21.65)
Alcohol drinking, Yes/total (%) Omega3Q10 11/24 (45.83) 0 11/48 (22.92)
Soybean oil 12/24 (50.0) 0 12/49 (24.49)
Combined 23/48 (47.92) 0 23/97 (23.71)
Hypercholesterolemia, Y/T, (%) Omega3Q10 12/24 (50.0) 10/24 (41.67) 22/48 (45.83)
Soybean oil 9/24(37.5) 7/25(28.0) 16/49 (32.65)
Combined 21/48 (43.75) 17/49 (34.69) 38/97 (39.18)
Elevated Blood Pressure, Y/T, (%) Omega3Q10 12/24 (50.0) 7/24 (29.17) 19/48 (39.58)
Soybean oil 11/24(45.83) 12/25(48.0) 23/49 46.93)
Combined 23/48 (47.92) 19/49 (38.78) 42/97 (43.30)
Coronary Heart Issues, Y/T, (%) Omega3Q10 1/24 (4.17) 2/24 (8.33) 3/48 (6.25)
Soybean oil 3/24 (12.5) 5/25 (20.0) 8/49 (16.33)
Combined 4/48 (8.33) 7/49 (14.29) 11/97 (11.34)
Stroke, Yes/total (%) Omega3Q10 0 1/24 (4.17) 1/48 (2.08)
Soybean oil 1/24 (4.17) 2/25 (8.0) 3/49 (6.12)
Combined 1/48 (2.08) 3/49 (6.12) 4/97 (4.12)
High Blood Sugar, Yes/total (%) Omega3Q10 2/24 (8.33) 1/24 (4.17) 3/48 (6.25)
Soybean oil 1/24 (4.17) 3/25 (12.0) 4/49 (8.16)
Combined 3/48 (6.25) 4/49 (8.16) 7/97 (7.21)
Kidney issues, Yes/total (%) Omega3Q10 0 0 0
Soybean oil 0 0 0
Combined 0 0 0
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P > 0.05, respectively) (Tables 3). However, both SBP and
DBP levels were reduced after either Omega3Q10 or
soybean oil treatment, with a significant DBP reduction
only found in the Omega3Q10 group. There are no
baseline differences in the blood pressure equilibrium
distribution (normal, high-normal (blood pressure), or
level I hypertension (mild)) according to the Guidance
for the prevention and management of elevated blood
pressure (2010 Chinese Edition) between the two groups
(χ2=0.907, P = 0.341) (Table 4).Hypertension-related symptoms
The results of Mann-Whitney U test showed no baseline
differences between the Omega3Q10 and soybean oil
groups in the self-reported hypertension-related symp-
tom severity scores of headaches (Z = 1.585, P = 0.113),
tinnitus (Z = 0.581, P = 0.561) and palpitations & chest
tightness (Z = 0.92, P = 0.358) except a significant
group difference in the distribution of dizziness scores
(Z = 2.785, P = 0.005) (Table 5). After the 12-week
intervention, however, more people in the Omega3Q10
group showed reduced symptom severities of headache
Table 2 Blood concentrations of cholesterol, LDL-C, HDL-C and
TC before and after 12-weeks intervention in Omega3Q10 and
soybean oil groups
Blood metabolites Before Intervention After Intervention
mmol/L (Median ± QR) mmol/L (Median ± QR)
LDL-C Omega3Q10 3.7 ± 0.8 3.3 ± 0.6*
Soybean oil 3.6 ± 0.7 3.4 ± 0.8*
(Z, P) 0.65, 0.51 0.57, 0.57
HDL-C Omega3Q10 1.25 ± 0.57 1.31 ± 0.54*
Soybean oil 1.0 ± 0.8 1.2 ± 0.7*
(Z, P) 0.90, 0.37 0.50, 0.62
TC Omega3Q10 5.5 ± 0.7 5.3 ± 0.5*
Soybean oil 5.7 ± 0.8 5.6 ± 0.7*
(Z, P) 0.38, 0.70 0.71, 0.48
*p < 0.05, within-group comparison of the after-treatment value with the
baseline
Table 4 Distribution of people with normal BP, pre-hypertension
and hypertension in Omega3Q10 and soybean oil groups
Blood pressure Omega3Q10 Soybean oil Total
n % n % n %
Baseline
Normal 0 0.0 4 8.2 4 4.1
Pre-hypertension 40 83.3 33 67.3 73 75.3
Hypertension 8 16.7 12 24.5 20 20.6
After intervention
Normal 1 2.1 5 10.2 6 6.2
Pre-hypertension 35 72.9 31 63.3 66 68.0
Hypertension 12 25.0 13 26.5 25 25.8
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palpitations & chest tightness (Z = 2.852, P = 0.004) than
the soybean oil group (Tables 6).
Discussion
Elevated blood lipid level and high-than-normal blood
pressures are independent risk factors of increased
cardiovascular dysfunction, chronic inflammation and
stroke [33–36]. Despite the development of pharma-
ceutical therapies and the recommendations of life
style modification, many people still fail to achieve
therapeutic goals [37–39]. Dietary supplements of fish
oil-derived n-3 PUFA or fish oil n-3 PUFA may re-
duce plasma cholesterol and LDL-C levels, and car-
diovascular risk [18, 20].
In this study, both Omega3Q10 and soybean oil
significantly reduced blood cholesterol and LDL-C levels
and, to a less extend, reduced blood pressures by Ome-
ga3Q10. in old adults with elevated blood pressure andTable 3 Mean blood pressures (mean ± s.d) before and after the
12-week intervention in Omega3Q10 and soybean oil groups
Blood pressure
(BP, mmHg)
Before intervention After intervention Declined value
Systolic BP
Omega3Q10 132.3 ± 5.5 130.7 ± 7.3 1.6 ± 7.3
Soybean oil 131.8 ± 9.3 129.7 ± 8.7 2.0 ± 10.4
(t, P) 0.36, 0.72 0.58, 0.56 0.22, 0.83
Diastolic BP
Omega3Q10 81.6 ± 5.3 79.3 ± 5.2* 2.3 ± 5.9
Soybean oil 80.4 ± 6.1 79.1 ± 5.3 1.3 ± 7.9
(t, P) 1.05, 0.30 0.20, 0.84 0.71, 0.48
*p < 0.05, within-group comparison of the after-treatment value with
the baselineblood cholesterol levels. Omega3Q10 also reduced the
symptom severities of headache and palpitations & chest
tightness. These results are in agreement with the
current knowledge that intake of n-3 polyunsaturated
fatty acid (PUFA) especially that of fish oil can reduce
the incidence of hypertension and cardiac mortality in
certain subpopulation [40–42], and in line with the re-
cent report that 12 months of omega 3 PUFA supple-
mentation significantly decreased systolic blood pressure
(SBP) (by 2.7 +/− 2.5 mmHg, p = 0.001) and diastolic
blood pressure (DBP) (by 1.3 +/− 3.3 mmHg, p < 0.001),
in 111 hypertriglyceridemic patients with untreated
normal-high blood pressure and with or without meta-
bolic syndrome [43].
Soybean oil was also effective in improving dyslipid-
emia probably because soybean oil contains n3-PUFA or
other potent ingredients that have cholesterol relieving
activities. Sterols, sterol esters and the sterol glycosides
present in soybean oil [44], can inhibit cholesterol ab-
sorption and lower LDL-C levels [45].
In this study, the daily dose of Omega3Q10 contains
514 mg PUFA (312 mg EPA (n3-PUFA) and 202 mg
DHA (n6-PUFA) whereas the daily dose of soybean oil
contains 115.48 mg PUFA (14 mg linolenic acid (n3-
PUFA), 100 mg linoleic acid (n6-PUFA) and 48 mg oleic
acid all of which have different cholesterol and LDL-C
lowering effects as well as cardioprotective effects albeit
with the fish n-3 PUFA having better efficacy. Other
studies showed that a 45-day supplement of high dose of
fish oil-derived n-3 PUFA (3 g/day) significantly reduced
systolic pressure [17]; high blood n-3 fatty acids levels
are associated with reduced risk of death, [46] and diet-
ary intake of linolenic acid is associated with a lower risk
of cardiovascular disease mortality. [47]. Additionally,
eating fish monthly can reduce the risk of ischemic
stroke. [48]. Epidemiological studies also support a
protective role of plant-derived n-3 fatty acid such as
alpha-linolenic acid (ALA), which was inversely related
Table 5 Baseline differences in blood pressure-related symptom severity scores between Omega3Q10 and soybean oil groups
(0 = no symptoms, 5 =most severe)
Symptom Group Symptom score (N/%) Z P
0 1 2 3 4 5
Dizziness Omega3Q10 31/64.6 6/12.5 6/12.5 1/2.1 4/8.3 0/0.0 2.785 0.005
Soybean oil 16/32.7 13/26.5 11/22.4 3/6.1 6/12.2 0/0.0
Headache Omega3Q10 36/75.0 5/10.4 4/8.3 2/4.2 1/2.1 0/0.0 1.585 0.113
Soybean oil 28/57.1 13/26.5 5/12.2 1/2.0 2/4.1 0/0.0
Tinitus Omega3Q10 38/79.2 6/12.5 3/6.3 1/2.1 0/0.0 0/0.0 0.581 0.561
Soybean oil 37/75.5 5/10.2 3/6.1 3/6.1 1/2.0 0/0.0
Palpitations & chest tightness Omega3Q10 40/83.3 3/6.3 2/4.2 2/4.2 1/2.1 0/0.0 0.920 0.358
Soybean oil 37/75.5 3/6.1 7/14.3 1/2.0 1/2.0 0/0.0
Other symptoms Omega3Q10 47/97.9 1/2.1 0/0.0 0/0.0 0/0.0 0/0.0 1.016 0.310
Soybean oil 46/93.9 1/2.0 1/2.0 1/2.0 0/0.0 0/0.0
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cardiovascular disease [49].
Genetic background may affect the efficacy of fish oil-
derived n-3 PUFA. A recent longitudinal study shows
that a higher omega-3 PUFA intake was associated with
a more pronounced blood pressure decrease over time
in subjects with the CYP4F2 433VV genotype [50].
Omega-3 PUFA may also reduce blood pressure by
acting as a substrate of cytochrome P450 (CYP450), the
enzymes involved in the production of vasoactive media-
tors. Functional polymorphisms (SNPs) in CYP450 genes
are associated with elevated blood pressure and ischemic
stroke [51–56]. Dietary fish oils have been shown to
have different preventive effects on the development of
elevated blood pressure and vascular response in differ-
ent genetic strains of rat [57]. Depending on rat strains
and fish oil composition, this was more pronounced for
fish oils enriched with EPA and DHA and was moreTable 6 Differences in hypertension-related symptom severity scores
intervention (0 = no symptoms, 5 =most severe)
Symptom Group Symptom score differ
0 1
Dizziness Omega3Q10 28/58.3 16/33.3
Soybean oil 27/55.1 12/24.5
Headache Omega3Q10 46/95.8 2/4.2
Soybean oil 35/71.4 12/24.5
Tinitus Omega3Q10 48/100.0 0/0.0
Soybean oil 46/93.9 1/2.0
Palpitations & chest tightness Omega3Q10 46/95.8 2/4.2
Soybean oil 37/75.5 10/20.4
Other symptoms Omega3Q10 48/100.0 0/0.0
Soybean oil 49/100.0 0/0.0prominent in the SHR and SHR/WKY backcross than it
was in the SHR-SP.
There is a possibility that ingredients such as vitamin
B of the Omega3Q10 formulation may have interacted
with n3- PUFA and n6-PUFA on cholesterol and LDL-C
levels as supplementation of B vitamins had no benefi-
cial effects on health-related quality of life in stroke and
cardiovascular disease survivors [58].
Fish oil-derived n-3 PUFA may exert its cardioprotec-
tive effects by anti-inflammatory mechanisms [59].
Long-term n3-PUFA dietary supplementation prevents
the development of intracranial atherosclerosis and
macrophage infiltration into the vessel wall, therefore re-
ducing inflammation and initial thickening in animals
[60]. Omega-3 PUFAs may exert their multiple health-
benefit effects partly by actions such as antagonizing
arachidonic acid-induced proinflammatory prostaglandin
E2 (PGE2) formation and by suppressing nuclear factor-between Omega3Q10 and soybean oil groups after the 12-weeks
ence (N/%) Z P
2 3 4 5
4/8.3 0/0.0 0/0.0 0/0.0 0.795 0.427
8/16.3 2/4.1 0/0.0 0/0.0
0/0.0 0/0.0 0/0.0 0/0.0 3.238 0.001
2/4.1 0/0.0 0/0.0 0/0.0
0/0.0 0/0.0 0/0.0 0/0.0 1.732 0.083
1/2.1 0/0.0 1/2.0 0/0.0
0/0.0 0/0.0 0/0.0 0/0.0 2.852 0.004
1/2.1 1/2.0 1/2.0 0/0.0
0/0.0 0/0.0 0/0.0 0/0.0 <0.001 1.000
0/0.0 0/0.0 0/0.0 0/0.0
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flammatory cytokines including interleukin-1beta, inter-
leukin 6 and tumor necrosis factor-α, which are
decreased by EPA and DHA [61–67] [68]. n-3 PUFAs
can also repress lipogenesis and increase resolvins and
protectin generation, thus reduced inflammation. EPA
and DHA benefit insulin resistance by inducing adipo-
nectin, an anti-inflammatory adipokine [67].
One study, however, showed that treatment with statin
alone or statin plus fish oil, but not fish oil alone,
reversed the increased plasma hs-CRP and IL-6 (a low-
grade chronic inflammatory state) in in 48 obese
individuals [69]. Marine omega-3 fatty acids also dose-
dependently regulated apolipoproteins, apolipoprotein-
defined lipoprotein subclasses, and Lp-PLA2 in individ-
uals with moderate hypertriglyceridemia [70]. It is
known that apolipoprotein (apo) distribution and lipo-
protein (Lp)-associated markers of inflammation, such
as lipoprotein-associated phospholipase A2 (Lp-PLA2),
influence the atherogenicity of circulating lipids and
lipoproteins.
Other multiple mechanisms may underlie the benefi-
cial effect of Omega3O10. It has been reported that the
antihypertensive effect of angiotensin converting enzyme
(ACE) inhibitors can be augmented by supplementing
fish oil [71]. Omega-3 PUFAs could regulate vasomotor
tone and renal sodium excretion, through competing
with omega-6 PUFAs for common metabolic enzymes
and thereby decreasing the production of vasocon-
strictor. PUFAs also reduce angiotensin-converting en-
zyme (ACE) activity, angiotensin II formation, tumor
growth factor-beta (TGF-b) expression, enhance endo-
thelial nitric oxide (NO) generation and activate the
parasympathetic nervous system, resulting in improved
vasodilation and arterial compliance of both small and
large arteries [72]. Indeed, fish oil attenuated adrenergic
overactivity without altering glucose metabolism during
an oral glucose load [73]. Omega-3 fatty acids improved
platelet redox balance in diabetic patients with hyperten-
sion [74]. Fish oil supplements increased the concentration
of phospholipid, improved membrane fluidity, decreased
the activity of HMG-CoA reductase in alloxan-induced
diabetic mice [75]. n-3 PUFA is also involved in the regula-
tion of mitochondrial 3-hydroxy-3-methylglutaryl-CoA
(HMG-CoA) synthase (HMGCS2) that catalyzes the first
step of ketogenesis and is critical in various metabolic
conditions [76].
In this study, participants who received soybean oil
capsule also showed improved cholesterol and LDL-C
levels. Studies have shown that, soybean oil contains n-3
PUFA and other active ingredients such as proteins,
phospholipids, lecithin, sterol and stanol, all of which
can affect cholesterol metabolism. Supplement of
soybean-derived lecithin for 2 years reduced serumcholesterol and triglycerides levels by 22% and 26%, re-
spectively, in people on low fat diet. [77]. Replacement
of dietary animal proteins with soy proteins for 4 weeks
significantly reduced blood cholesterol by 18.6% and im-
proved HDL-C, in 65 people with hyperlipidemia [78].
And novel soybean oils differing in linoleic acid (LA)
and alpha-linolenic acid (ALA) ratio and n-6/n-3 ratio
can alter immune functions. [79], and serum cholesterol
and triglyceride levels, respectively [80].
Several meta-analyses reported that daily intake of
up to 2 g of stanols or sterols can reduce blood LDL-
C by 10% (or by 20% if on low fat/cholesterol diet or
on statin medication) [81–84]. However, because
sterol-enriched foods increase plasma sterol levels and
the risk of atherosclerosis in patients with homozy-
gous phytosterolemia [45, 85, 86], further studies are
needed to determine the optimal dose range in differ-
ent subpopulations.Limitations
There are limitations of this pilot study. The number of
the participants, the selection of the dosage of Ome-
ga3Q10 supplement and the control group (soy oil) were
not optimized for detecting potential effects of Ome-
ga3Q10 on the studied parameters. For example, the
originally calculated sample size (N = 45 per group, with
10% drop rate) was based on the assumption of a base-
line value of 3.7 ± 0.7 mmol/L of LDL-C in the Ome-
ga3Q10 and soybean oil group that would be decreased
to 3.3.0 ± 0.6 mmol/L after 12-week Omega3Q10 inter-
vention and no change after soybean oil intervention.
But the results show that soy oil tended to produce simi-
lar effects as that of Omega3Q10 probably due to the
presence of plant sterols and other active PUFA ingredi-
ents in soy oil.
The concurrent use of different anti-hypertension and
anti-dyslipidemia drugs by a significant portion of the
participants in the Omega3Q10 group (42.1%) and in
the Soy Oil group (58.5%) would also make it difficult to
discern the true effects of the Omega3Q10 and Soy oil
on blood pressure and blood lipid profile.
Previous studies showed that both statin therapy (sim-
vastatin (40 mg/d) and co-supplements of red yeast rice
(a natural source of statins) and fish oil for 12 weeks
significantly reduced LDL-C levels (−39.6% vs. −42.4%,
P < .001 and P < .001) [87]. And co-administration of
omega-3 fatty acids (4.2 g/d) with statin for 8-weeks sig-
nificantly increased LDL particle size and decreased TG
level in dyslipidemic patients with type 2 diabetes and
without causing significant adverse effects [88]. Further-
more, co-administration of omega-3 (EPA 465 mg;
DHA, 375 mg; othern-3 FA, 60 mg) and statins (simva-
statin 20 mg /d) for 6 weeks produced greater reduction
Shen et al. Lipids in Health and Disease  (2017) 16:253 Page 8 of 11in TG than statin monotherapy (41% reduction vs 13.9%
reduction, P < 0.01) [89].
Other studies show that statin alone or co-treatment
with fish oil, but not fish oil alone, reversed increased
plasma hs-CRP and IL-6 and, hence reduced chronic in-
flammatory state in visceral obesity [69]. In addition, the
triglyceride-lowering effect of atorvastatin, but not fish
oils, is associated with increased VLDL apo C-III frac-
tional catabolism and hence lower VLDL apo C-III con-
centrations. Co-treatment provided no significant
additional improvement in VLDL apo C-III metabolism
compared with atorvastatin alone [90].
Recent studies have also showed that 16-week of co-
administration of plant sterols esters (1300 mg), fish oil
(1000 mg EPA and DHA) and vitamins B12 (50 mug),
B6 (2.5 mg), folic acid (800 mug) and coenzyme Q10
(3 mg) significantly reduced total cholesterol, LDL- chol-
esterol, VLDL-cholesterol, subfractions LDL-2, IDL-1,
IDL-2 and plasma homocysteine levels and decreased
triacylglycerols levels at a trend level (by 17.6%) in hy-
percholesterolemic children and adolescents [91]. Fish-
oil esters of plant sterols improve the lipid profile of dys-
lipidemic subjects more than do fish-oil or sunflower oil
esters of plant sterols [92]. Low doses of fish oil-derived
EPA and DHA plus plant sterols also dose-dependently
decreased serum triglyceride concentrations in hyper-
cholesterolemic men and women [93]. These studies to-
gether with our current findings suggest potential
additive benefits of co-administration of n-3 PUFAs and
plant sterols for people with increased risk of cardiovas-
cular conditions and that should be evaluated in future
better-controlled, large-scale studies.
In this study, we also conducted multivariate regres-
sion analysis, with intervention groups as the primary
variable of interest. The covariates were baseline
smoking status (yes/no), current medicine use (yes/no),
baseline DBP (mmHg), and baseline cholesterol level
(baseline TC/baseline HDL/baseline LDL). No significant
differences were found between the Omega3Q10 and
soybean oil in blood pressures (SBP/DBP) or in choles-
terol (LDL/TC/HDL) after the potential confounders
were controlled, suggesting that both Omega3Q10 and
soybean oil supplementation had similar effects on blood
cholesterol and blood pressure. We did notice, however,
that after controlling the current medicine use (taken
by 42.1% of the Omega3Q10 group and by 58.5% of
the Soy Oil group), the LDL-C results showed a trend
difference (P < 0.18) between the Omega3Q10 and
Soybean oil group. Because the number of people is
very small and the medicine varied greatly (anti-
hypertension or lipid-lowering etc.), further studies
should determine if Omega3Q10 and soybean oil could
interact differently with different anti-hypertension and
anti-dyslipidemia drugs.Conclusions
Dietary supplementation of Fish oil-based Omega3Q10
were safe and effective in reducing blood pressure and
blood cholesterol and LDL-C levels in old adults with
hypertension and hypercholesterolemia. Omega3Q1 also
appears to be more effective than soybean oil in improv-
ing DBP and hypertension-related symptoms in old
adults with hypertension and hypercholesterolemia al-
though both supplementation improved TC, LDL-C and
HDL-C concentrations.
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